Julie Kreyenbuhl, Pharm.D., Ph.D., is a Research Investigator and Associate Director of the Research Core for the VA VISN 5 Mental Illness Research, Education, and Clinical Center (MIRECC) and an Associate Professor of Psychiatry in the Division of Psychiatric Services Research, Department of Psychiatry, University of Maryland School of Medicine. Dr. Kreyenbuhl received a Pharm.D. from Mercer University College of Pharmacy and Health Sciences and a Ph.D. in Pharmaceutical Health Services Research from the University of Maryland School of Pharmacy. She also completed a post-doctoral fellowship at the Maryland Psychiatric Research Center.
Dr. Kreyenbuhl's primary research interest is the pharmacoepidemiology of serious mental illness. She was the recipient of a K01 Research Career Award from NIMH that focused on prescription decision-making and patterns of use of complex, multidrug regimens in schizophrenia. Dr. Kreyenbuhl has contributed extensively to the development of evidence-based treatment guidelines for schizophrenia, serving as a co-investigator on the first update and principal investigator of grants funded by the NIMH and the VA to support the second update of the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. She also served as a consultant to the American Psychiatric Association during their last effort to update the Practice Guideline for the Treatment of Patients with Schizophrenia. In addition, Dr. Kreyenbuhl has expertise in the area of medication adherence and has received support from the Brain and Behavior Research Foundation to evaluate adherence to antipsychotic and oral hypoglycemic medications in individuals with schizophrenia and Type 2 diabetes. She is also interested in methods to improve screening for the metabolic side effects of antipsychotic medications. She has received grant funding from VA HSR&D to determine if providing computerized, personalized health information directly to veterans with serious mental illnesses on whether their care adheres to screening guidelines for metabolic side effects increases rates of screening and activates patients to discuss screening with their providers. She is also the PI, Co-PI, or co-investigator on other funded efforts to study computer-technology based interventions for individuals with serious mental illnesses, including the development and testing of a Smartphone application for enhancing adherence to antipsychotic medications. Dr. Kreyenbuhl has authored or co-authored over 60 publications in peer-reviewed journals.